Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Monitoring the responsiveness of T and antigen presenting cell compartments in breast cancer patients is useful to predict clinical tumor response to neoadjuvant chemotherapy

Fig. 2

DC maturation and IL-12p70 production are hampered in cancer patients before treatment. a The analysis by contour plots of a representative sample of myeloid (HLA-DR+ Lin1- CD11c+) and plasmacytoid (HLA-DR+ Lin1- CD123+) DCs is shown. b Representative histograms comparing the phenotype (CD83, CCR7, and CD86) of immature (empty histogram) and mature (gray histogram) in myeloid DCs (HLA-DR+ Lin1- CD11c+) derived from HD. c Quantification of CD83 expression in response to maturation stimulus (delta of the percentage of CD83 expression between mature and immature DCs) in DCs derived in PBMCs from HD (white box), and breast cancer patients before and after chemotherapy (grey and dashed box, respectively) in monocytic cells (defined by FSC-A vs SSC-A (left)), myeloid (HLA-DR+ Lin1- CD11c + (middle)) or plasmacytoid DCs (HLA-DR+ Lin1- CD123+ (right)). d Delta of concentration in pg/mL of IL-12p70 secreted in culture supernatants (difference in concentration secreted by mature and immature) DCs from HD (white box, n = 10) and patients before (gray box, n = 17) and after chemotherapy (dashed box, n = 17). Boxes and whiskers 10–90%, two-way ANOVA analysis, with Turkey’s multiple comparison tests, * p < 0.05, ** p < 0.01

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us